(2019). Endogenous CD4+ TCells Recognize Neoantigens in Lung Cancer Patients, Including RecurrentoncogenicKRAS and ERBB2 (Her2) driver mutationsEndogenous CD4+ TCells Recognize Neoantigens in Lung Cancer Patients, Including RecurrentOncogenic ) Driver Mutations. Cancer Immunol.